Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)

被引：0
|
作者：
Sznol, Mario
Kluger, Harriet M.
Callahan, Margaret K.
Postow, Michael Andrew
Gordon, Ruth Ann
Segal, Neil Howard
Rizvi, Nalyer A.
Lesokhin, Alexander M.
Atkins, Michael B.
Kirkwood, John M.
Burke, Matthew M.
Ralabate, Amanda L.
Rivera, Angel L.
Kronenberg, Stephanie Anne
Agunwamba, Blessing
Feely, William
Hong, Quan
Krishnan, Suba
Gupta, Ashok Kumar
Wolchok, Jedd D.
机构：
[1] Yale Canc Ctr, New Haven, CT USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[4] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[5] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA9003
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
    Sznol, Mario
    Kluger, Harriet M.
    Callahan, Margaret K.
    Postow, Michael Andrew
    Gordon, Ruth Ann
    Segal, Neil Howard
    Rizvi, Naiyer A.
    Lesokhin, Alexander M.
    Atkins, Michael B.
    Kirkwood, John M.
    Burke, Matthew M.
    Ralabate, Amanda L.
    Rivera, Angel L.
    Kronenberg, Stephanie Anne
    Agunwamba, Blessing
    Feely, William
    Hong, Quan
    Krishnan, Suba
    Gupta, Ashok Kumar
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (18)
  • [2] SURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIAL OF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL)
    Kluger, H.
    Sznol, M.
    Callahan, M.
    Postow, M.
    Gordon, R.
    Segal, N. H.
    Rizvi, N.
    Lesokhin, A.
    Atkins, M. B.
    Kirkwood, J.
    Burke, M.
    Ralabate, A.
    Rivera, A.
    Kronenberg, S.
    Agunwamba, B. U.
    Feely, W.
    Hong, Q.
    Krishnan, S.
    Wolchok, J.
    ANNALS OF ONCOLOGY, 2014, 25
  • [3] Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)
    Wolchok, Jedd D.
    Kluger, Harriet M.
    Callahan, Margaret K.
    Postow, Michael Andrew
    Gordon, Ruth Ann
    Segal, Neil Howard
    Rizvi, Naiyer A.
    Lesokhin, Alexander M.
    Reed, Kathleen
    Burke, Matthew M.
    Caldwell, Anne
    Kronenberg, Stephanie Anne
    Agunwamba, Blessing
    Feely, William
    Hong, Quan
    Horak, Christine E.
    Korman, Alan J.
    Wigginton, Jon M.
    Gupta, Ashok Kumar
    Sznol, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Combined nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab in the treatment of advanced melanoma (MEL) patients (pts): Safety and clinical activity
    Sznol, M.
    Callahan, M. K.
    Kluger, H.
    Postow, M. A.
    Burke, M.
    Hong, Q.
    Selby, M.
    Korman, A.
    Gupta, A.
    Wolchok, J. D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S866 - S866
  • [5] Phase 2 study of nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in patients with advanced melanoma
    Yamazaki, N.
    Tahara, H.
    Uhara, H.
    Moroi, Y.
    Kiyohara, Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S868 - S868
  • [6] SURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS OF NIVOLUMAB (NIVO, ANTI-PROGRAMMED DEATH-1) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL)
    Sznol, Mario
    Kluger, Harriet
    Callahan, Margaret K.
    Postow, Michael A.
    Gordon, RuthAnn
    Seal, Neil H.
    Rizvi, Naiyer A.
    Lesokhin, Alexander M.
    Atkins, Michael B.
    Kirkwood, John M.
    Burke, Matthew M.
    Ralabate, Amanda
    Rivera, Angel
    Kronenberg, Stephanie A.
    Agunwamba, Blessing U.
    Feely, William
    Quan, Hong
    Krishnan, Suba
    Gupta, Ashok
    Wolchok, Jedd D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 188 - 188
  • [7] Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.
    Callahan, Margaret K.
    Horak, Christine E.
    Curran, Michael A.
    Hollman, Travis
    Schaer, David A.
    Yuan, Jianda
    Lesokhin, Alexander M.
    Kitano, Shigehisa
    Hong, Quan
    Ariyan, Charlotte Eielson
    Busam, Klaus J.
    Feely, William
    Jure-Kunkel, Maria
    Grosso, Joseph
    Simon, Jason S.
    Korman, Alan J.
    Wigginton, Jon M.
    Gupta, Ashok Kumar
    Sznol, Mario
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
    Michael A Postow
    Diana M Cardona
    Janis M Taube
    Robert A Anders
    Clive R Taylor
    Jedd D Wolchok
    Margaret K Callahan
    Michael A Curran
    Alexander M Lesokhin
    Joseph F Grosso
    Christine E Horak
    John Cogswell
    Jason S Simon
    Ashok K Gupta
    Mario Sznol
    Journal of Translational Medicine, 12 (Suppl 1)
  • [9] An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL)
    Sosman, Jeffrey Alan
    Martin-Algarra, Salvador
    Wolchok, Jedd D.
    Sharfman, William Howard
    Bhatia, Shailender
    Hodi, F. Stephen
    Hwu, Wen-Jen
    Gajewski, Thomas
    Slingluff, Craig L.
    Kaufman, Howard
    Gupta, Manish
    McGirr, Analia
    Horak, Christine E.
    Ahlers, Christoph Matthias
    Wigginton, Jon M.
    Urba, Walter John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Phase 2 study of Nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in Japanese patients with advanced melanoma: Preliminary report
    Yamazaki, N.
    Kiyohara, Y.
    Uhara, H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S110 - S110
12345